Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis

+0.02 (+1.25%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
2,182 shs
Average Volume
7,756 shs
Market Capitalization
$22.97 million
P/E Ratio
Dividend Yield
Price Target
CPIX stock logo

About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX)

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CPIX Stock Price History

CPIX Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
See More Headlines
Receive CPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$39.55 million
Cash Flow
$0.70 per share
Book Value
$1.96 per share


Free Float
Market Cap
$22.97 million

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. A. J. Kazimi MBA (Age 66)
    Founder, Chairman, President & CEO
    Comp: $952.53k
  • Mr. John Michael Hamm (Age 68)
    VP & CFO
    Comp: $258.38k
  • Mr. James Lowrance Herman (Age 69)
    Executive VP of National Accounts & Chief Compliance Officer
    Comp: $372.27k
  • Mr. Chris T. Bitterman (Age 59)
    Vice President of Sales & Marketing
    Comp: $290.87k
  • Mr. Todd M. Anthony (Age 63)
    Vice President of Organizational Development
    Comp: $304.94k
  • Ms. Jean W. Marstiller (Age 74)
    Senior VP of Administrative Services & Corporate Secretary
    Comp: $282.17k
  • Mr. Adam S. Mostafa (Age 44)
    Managing Director
  • Ms. Erin Smith Gull
    Senior Corporate Relations Associate

CPIX Stock Analysis - Frequently Asked Questions

How have CPIX shares performed in 2024?

Cumberland Pharmaceuticals' stock was trading at $1.7917 at the beginning of 2024. Since then, CPIX stock has decreased by 9.6% and is now trading at $1.62.
View the best growth stocks for 2024 here

Are investors shorting Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 17,000 shares, a drop of 16.7% from the March 15th total of 20,400 shares. Based on an average daily volume of 11,800 shares, the short-interest ratio is presently 1.4 days. Currently, 0.2% of the shares of the company are short sold.
View Cumberland Pharmaceuticals' Short Interest

When is Cumberland Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CPIX earnings forecast

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its quarterly earnings results on Tuesday, March, 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $9.35 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 15.87% and a positive trailing twelve-month return on equity of 6.84%.

What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO?

9 employees have rated Cumberland Pharmaceuticals Chief Executive Officer A. J. Kazimi on A. J. Kazimi has an approval rating of 9% among the company's employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), Xeris Biopharma (XERS).

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CPIX) was last updated on 4/23/2024 by Staff

From Our Partners